f20785b9-991d-4b87-8ba7-ca32373f1996
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.600
- MYC_TARGETS_V1+0.600
- MYC_TARGETS_V2+0.600
- OXIDATIVE_PHOSPHORYLATION+0.600
- G2M_CHECKPOINT+0.500
- CHOLESTEROL_HOMEOSTASIS+0.400
- DNA_REPAIR+0.400
- FATTY_ACID_METABOLISM+0.400
- MTORC1_SIGNALING+0.400
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.400
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.400
- IL6_JAK_STAT3_SIGNALING-0.400
- TGF_BETA_SIGNALING-0.400
- UV_RESPONSE_DN-0.400
- HEDGEHOG_SIGNALING-0.300
- INFLAMMATORY_RESPONSE-0.300
- INTERFERON_ALPHA_RESPONSE-0.300
- INTERFERON_GAMMA_RESPONSE-0.300
- KRAS_SIGNALING_DN-0.300
- KRAS_SIGNALING_UP-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 4613d81b-e9ba-4c36-96a5-d7c9667b83ec | — | — | 0.913 |
| 2 | SRR17866857 | — | — | 0.886 |
| 3 | fddf611e-f586-49e1-9ee8-8ac853accb9e | — | — | 0.881 |
| 4 | AUR-AFUM-TTM1-A-1-1-R-A743-41 | — | E | 0.878 |
| 5 | SRR11296846 | — | — | 0.875 |
| 6 | SRR975598 | — | — | 0.872 |
| 7 | 0acddbbc-6b74-4fdd-903d-f5ec9bfd8514 | — | — | 0.871 |
| 8 | TCGA-22-5485-01A-01R-1635-07 | — | cohortSQ2 | 0.870 |
| 9 | 8c76ce45-f110-4f6a-b413-13a1a1aeddef | — | — | 0.869 |
| 10 | TCGA-CV-5432-01A-02R-1686-07 | — | — | 0.868 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.600 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.600 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.600 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.600 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.500 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.400 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.400 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.400 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.400 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.400 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.300 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.300 | Inavolisib | — uncovered |
| PEROXISOME | 0.200 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.200 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.200 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.100 | Temsirolimus | — uncovered |
| NOTCH_SIGNALING | 0.100 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.100 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |